Loading...

APC anti-human CD340 (erbB2/HER-2) Antibody

Pricing & Availability
Clone
24D2 (See other available formats)
Regulatory Status
RUO
Other Names
HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, oncogene NGL, neuroblastoma- or glioblastoma-derived, HER-2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
24D2_APC_072607
Human breast cancer cell line (MCF-7) stained with 24D2 APC
  • 24D2_APC_072607
    Human breast cancer cell line (MCF-7) stained with 24D2 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
324407 25 tests 149 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
324408 100 tests 314 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD340 is also known as HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, and oncogene NGL, neuroblastoma- or glioblastoma-derived. It is a member of the epidermal growth factor receptor family of cell membrane tyrosine kinases containing a single transmembrane domain and has an approximate molecular weight of 185 kD. CD340 contains three furin repeats and two cheY homologous receiver domains in the extracellular region (ECR). The HER2/erbB2 protein is expressed on many tumor cells, including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow mesenchymal stem cells. Although the erbB2/HER2 protein contains no ligand binding domain, this protein interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. CD340 has been shown to be involved in embryonic development and cancer progression; this protein is amplified in adenocarcinoma of the lung, some breast cancers, glioblastoma, gastric cancer, and ovarian carcinoma, where it functions as an oncogene. Overexpression of erbB2 in breast cancers has been shown to confer Taxol resistance and is a therapeutic target in a number of human cancers. The erbB2/HER-2 protein has been shown to interact with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others. CD340 is extensively modified by tyrosine phosphorylation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NIH-3T3 transfected with human HER-2
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application References

(PubMed link indicates BioLegend citation)
  1. Bühring HJ, et al. 1995. Blood 86:1916.
Product Citations
  1. Falahi F, et al. 2013. Mol Cancer Res. 11:1029. PubMed
  2. Bergado-Baez G, et al. 2022. Front Oncol. 12:951267. PubMed
  3. Yu J, et al. 2023. EBioMedicine. 89:104451. PubMed
  4. Pham TC, et al. 2021. J Extracell Vesicles. e12057:10. PubMed
  5. Gabaev I, et al. 2020. Cell Rep. 33:108249. PubMed
  6. Klichinsky M, et al. 2020. Nat Biotechnol. 38:947. PubMed
  7. Zabransky DJ, et al. 2015. Proc Natl Acad Sci U S A. 112: 6205 -6214. PubMed
  8. Bose R, et al. 2013. Cancer Discovery. 3:224. PubMed
  9. Marrocco I, et al. 2021. EMBO Mol Med. 13:e13144. PubMed
  10. Urbanova L, et al. 2017. Immunology Letters. 10.1016/j.imlet.2017.05.005. PubMed
  11. Liu Z, et al. 2021. Oncogene. 40:6273. PubMed
  12. Matlung HL et al. 2018. Cell reports. 23(13):3946-3959 . PubMed
  13. O'Geen H, et al. 2019. Epigenetics Chromatin. 12:26. PubMed
RRID
AB_756123 (BioLegend Cat. No. 324407)
AB_756123 (BioLegend Cat. No. 324408)

Antigen Details

Structure
Member of the epidermal growth factor receptor family of cell membrane tyrosine kinases. Single transmembrane pass protein with an approximate molecular weight of 185 kD. Contains three furin repeats and two cheY homologous receiver domains in the ECR.
Distribution

Expressed on many tumor cells including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow MSCs.

Function
Contains no ligand binding domain and interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. Involved in embryonic development and cancer progression.
Interaction
CD340 (HER2/erbB2) interacts with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others.
Modification
Extensively modified by tyrosine phosphoryation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).
Cell Type
Leukemia
Biology Area
Cell Biology, Immunology, Neuroscience, Synaptic Biology
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Akiyama T, et al. 1986. Science 232:1644.
2. Bargmann CI, et al. 1986. Nature 319:226.
3. Pegram MD, et al. 1997. Oncogene 15:537.
4. Slamon DJ, et al. 1989. Science 244:707.
5. Leone F, et al. 2003. J. Leukocyte Biol. 74:593.

Gene ID
2064 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD340
Specificity Alt (DOES NOT SHOW ON TDS):
CD340
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD340 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account